The main goal of this project is to investigate whether dietary isoflavones such as genistein can inhibit prostate cancer growth through activation of tumor suppressor microRNAs (miRNAs) using both in vitro and in vivo models. Prostate cancer is the most common male malignancy and the second leading cause of cancer death among men in the United States. The rationale for this project is that recent studies have shown significant effects of diet on modulation of miRNAs using both in vitro and in vivo models. Based on our preliminary data and published literature, we hypothesize that genistein can activate a set of tumor suppressor miRNAs thereby inhibiting prostate cancer progression through two different pathways. First, genistein induced tumor suppressor miRNAs can repress oncogene expression by binding to the 3'untranslated region of mRNA (3'UTR). Second genistein induced tumor suppressor miRNAs can activate the transcription of tumor suppressor genes by binding to the 5'upstream region of the gene or activate translation by binding to the 5'untranslated region of mRNA (5'UTR). This project is novel and timely because the roles of genistein mediated activation of tumor suppressor miRNAs in the regulation of prostate cancer progression have not been investigated. We also hypothesize that the molecular mechanism of genistein's mediated activation of tumor suppressor miRNAs are through epigenetic pathways. These hypotheses will be tested by pursuing the following three specific aims.
Specific Aim # 1. To test the hypothesis that genistein mediated activation of tumor suppressor microRNAs are involved in the regulation of prostate cancer.
Specific Aim # 2: To test the hypothesis that DNA methylation and histone modifications are the key mechanisms of genistein mediated activation of microRNAs in prostate cancer.
Specific Aim # 3: To test the hypothesis that genistein can suppress prostate cancer growth in a nude mouse model through activation of microRNAs. Impact: The project will provide a novel paradigm with high impact in the field of management of prostate cancer since dietary mediated activation of tumor suppressor miRNAs and their roles in the inhibition of prostate cancer progression have never been investigated. Successful accomplishment of these experiments will provide novel strategies for the treatment of prostate cancer.

Public Health Relevance

Prostate cancer is the most common male malignancy and the second leading cause of cancer death among men in the United States. The rationale for this project is that recent studies have shown significant effects of diet on modulation of miRNAs using both in vitro and in vivo models. Based on our preliminary data and published literature, we hypothesize that genistein can activate a set of tumor suppressor miRNAs thereby inhibiting prostate cancer progression through different pathways. The major barrier to progress in the management of prostate cancer is the high toxicity of the drugs currently in use. The present proposal will address this problem by investigating the use of dietary methods for the management of prostate cancer in both in vitro and in vivo models. We have proposed a series of experiments to investigate the role of genistein in the regulation of prostate cancer progression through modulation of tumor suppressor miRNAs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA160079-03
Application #
8458611
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Ross, Sharon A
Project Start
2011-07-06
Project End
2016-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
3
Fiscal Year
2013
Total Cost
$429,926
Indirect Cost
$139,827
Name
Northern California Institute Research & Education
Department
Type
DUNS #
613338789
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Imai-Sumida, Mitsuho; Chiyomaru, Takeshi; Majid, Shahana et al. (2017) Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget 8:92032-92042
Colden, Melissa; Dar, Altaf A; Saini, Sharanjot et al. (2017) MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis 8:e2572
Mitsui, Yozo; Chang, Inik; Kato, Taku et al. (2016) Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer. Oncotarget 7:49107-49121
Shahryari, Varahram; Nip, Hannah; Saini, Sharanjot et al. (2016) Pre-clinical Orthotopic Murine Model of Human Prostate Cancer. J Vis Exp :
Nip, Hannah; Dar, Altaf A; Saini, Sharanjot et al. (2016) Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget 7:68371-68384
Hirata, Hiroshi; Hinoda, Yuji; Shahryari, Varahram et al. (2015) Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res 75:1322-31
Saini, Sharanjot; Majid, Shahana; Shahryari, Varahram et al. (2014) Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther 13:1952-63
Chiyomaru, Takeshi; Fukuhara, Shinichiro; Saini, Sharanjot et al. (2014) Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J Biol Chem 289:12550-65
Hirata, H; Hinoda, Y; Shahryari, V et al. (2014) Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer 110:1645-54
Arora, Sumit; Saini, Sharanjot; Fukuhara, Shinichiro et al. (2013) MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. PLoS One 8:e78023

Showing the most recent 10 out of 24 publications